相似文献
1
Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost.
Heart. 2004 Jan;90(1):e2. doi: 10.1136/heart.90.1.e2.
2
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group.
J Am Coll Cardiol. 2000 Jan;35(1):176-82. doi: 10.1016/s0735-1097(99)00494-5.
3
Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance.
Eur J Cardiothorac Surg. 2002 Nov;22(5):746-52. doi: 10.1016/s1010-7940(02)00488-8.
4
Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension.
Int J Cardiol. 2007 Jan 31;115(1):67-72. doi: 10.1016/j.ijcard.2006.01.067. Epub 2006 Jun 23.
5
Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension.
Eur Respir J. 2004 Feb;23(2):321-6. doi: 10.1183/09031936.03.00057703.
6
[SPECIFICS OF INHALED ILOPROST PHARMACODYNAMICS IN PATIENTS WITH SEVERE LEFT VENTRICULAR SYSTOLIC DYSFUNCTION].
Anesteziol Reanimatol. 2015 Mar-Apr;60(2):4-7.
7
Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease.
Catheter Cardiovasc Interv. 2009 Jan 1;73(1):98-104. doi: 10.1002/ccd.21793.
8
Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.
Circulation. 2001 Sep 11;104(11):1218-22. doi: 10.1161/hc3601.096826.
9
Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.
Am J Respir Crit Care Med. 1999 Aug;160(2):600-7. doi: 10.1164/ajrccm.160.2.9810008.
10
A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.
Heart Vessels. 2017 Dec;32(12):1488-1497. doi: 10.1007/s00380-017-1023-2. Epub 2017 Jul 17.
引用本文的文献
1
The effect of iloprost and sildenafil, alone and in combination, on myocardial ischaemia and nitric oxide and irisin levels.
Cardiovasc J Afr. 2017;28(6):389-396. doi: 10.5830/CVJA-2017-025. Epub 2017 Aug 31.
本文引用的文献
1
Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue.
Heart. 2001 Dec;86(6):661-5. doi: 10.1136/heart.86.6.661.
2
Current management of primary pulmonary hypertension.
Drugs. 2001;61(13):1945-56. doi: 10.2165/00003495-200161130-00005.
3
New and experimental therapies for pulmonary hypertension.
Clin Chest Med. 2001 Sep;22(3):539-45. doi: 10.1016/s0272-5231(05)70290-2.
4
Medical therapy of pulmonary hypertension. The prostacyclins.
Clin Chest Med. 2001 Sep;22(3):529-37, x. doi: 10.1016/s0272-5231(05)70289-6.
5
Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion.
Heart. 2001 Sep;86(3):E10. doi: 10.1136/heart.86.3.e10.
6
Recommendations on the management of pulmonary hypertension in clinical practice.
Heart. 2001 Sep;86 Suppl 1(Suppl 1):I1-13.
7
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.
Eur Respir J. 1998 Aug;12(2):265-70. doi: 10.1183/09031936.98.12020265.
8
Primary pulmonary hypertension in children: clinical characterization and survival.
J Am Coll Cardiol. 1995 Feb;25(2):466-74. doi: 10.1016/0735-1097(94)00391-3.
9
High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.
Circulation. 1987 Jul;76(1):135-41. doi: 10.1161/01.cir.76.1.135.
Zotero 插件